Is PM a Buy? What to Consider in 2026

The case for Philip Morris International right now is IQOS heated tobacco leadership, with revenue (ttm) at ~$40 billion, growing high single digits; Q1 2026 net revenues rose about 9% year over year. If you believe that thesis holds, PM is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is regulation is the dominant risk: tobacco and nicotine face constant scrutiny, and the US FDA's stance on nicotine pouches, flavors, and youth use could restrict or slow ZYN and other products in PMI's most promising growth market. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.

Philip Morris International is one of the world's largest tobacco and nicotine companies, selling Marlboro and other cigarette brands across roughly 180 markets outside the United

Regulation is the dominant risk: tobacco and nicotine face constant scrutiny, and the US FDA's stance on nicotine pouches, flavors, and youth use could restrict or slow ZYN and other products in PMI's most promising growth market. Combustible cigarette volumes are in secular decline, so the whole thesis depends on smoke-free products growing fast enough to offset that erosion. As an international operator reporting in dollars, PMI carries meaningful currency risk, and a strong dollar can weigh on reported revenue and earnings. ESG mandates lead many funds and investors to exclude tobacco entirely, capping the buyer base. The company also carries a large debt load from the Swedish Match acquisition, and litigation, excise-tax hikes, and illicit-trade competition remain persistent overhangs. Finally, a high payout ratio leaves less room for error if growth or cash flow disappoints.

That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is a genuine growth story inside a defensive tobacco business: IQOS and ZYN are pushing smoke-free products toward half of revenue, EPS is guided to grow low double digits, and PMI pays a rising, above-market dividend. The bear case is heavy regulatory and FDA risk, secular cigarette decline, ESG exclusion, debt from the Swedish Match deal, and currency exposure. Weigh both against your portfolio.

PMI is a global tobacco and nicotine company that sells cigarettes, including Marlboro, across roughly 180 markets outside the US, and increasingly sells smoke-free products. Its smoke-free portfolio is led by IQOS heated tobacco, ZYN nicotine pouches, and VEEV vapes, which together reached about 43% of net revenues in early 2026 as the company shifts away from combustible cigarettes.

They split from the same company in 2008 and divided Marlboro by geography: Altria sells Marlboro in the US, while PMI sells it in the rest of the world. Altria is US-focused, slower-growing, and carries a higher dividend yield, whereas PMI is international, growing faster through IQOS and ZYN, and yields somewhat less. They are separate companies with different footprints, not two share classes of one business.

IQOS is PMI's heated-tobacco device that warms rather than burns tobacco, and it leads the global heat-not-burn category. ZYN is a tobacco-free nicotine pouch that PMI gained through its 2023 Swedish Match acquisition and that dominates the US pouch market with roughly 70% share. Both are central to PMI's smoke-free transition and are its main growth drivers, especially ZYN in the United States.